Xencor_XmAb819-01 (Clear Cell Renal Cell Carcinoma)

Purpose of this Study

We are doing this study to find out if an experimental drug called XmAb819 (the study drug) is a safe and effective treatment for clear cell renal cell carcinoma (ccRCC).

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with ccRCC
  • Have not improved after receiving standard therapy
For more information about who can join this study, please contact the study team at 919-681-6468.

What is Involved?

Description

If you choose to join this study, you will:
  • Get the study drug as either an intravenous infusion (IV) or as an injection under your skin
  • Have a tumor biopsy
  • Have physical exams, blood draws, and give urine samples
  • Have imaging scans (CT and/or MRI)
  • Have heart tests (ECG)

Study Details

Full Title

A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma

Principal Investigator

Christopher
Hoimes

Protocol Number

PRO00111480

NCT ID

NCT05433142

Phase

I

Enrollment Status

Open to Enrollment
ClinicalTrials.gov